Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial

作者：Patrice Sévère, Samuel Pierre, Fabienne Homeus, Jean Bernard Marc, Letizia Trevisi, Maria Linda Aristhomene, Guirlaine Bernadin, Kerlyne Lavoile, Vanessa R. Rivera, Carl Frédéric Duchatellier, Mano Joseph, John C. Wu, Vanessa Rouzier, Fabiola Préval, Evens Jean, Jodany Bernadin, Abigail Zion, Guyrlaine Pierre Louis Forestal, Santiago Ávila‐Ríos, Claudia García Morales, Adina Zhang, Dennis M Israelski, Alexandra Apollon, Emelyne Droit Dumont, Elizabeth Fox, Pierre‐Yves Crémieux, Jean William Pape, Sean E Collins, Bernard Liautaud, Paul Edward Sax, Serena P. Koenig · 发表于：The Lancet HIV · 年份：2025 · DOI：10.1016/s2352-3018(25)00130-4 · 被引用次数：5 · 研究领域：HIV/AIDS drug development and treatment、HIV-related health complications and treatments、HIV/AIDS Research and Interventions